INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, ...
Barchart on MSN
5 Under-the-Radar Biotech Stocks That Could Soar in 2026
The biotech sector has long offered investors high-risk, high-reward stocks. While large players are making headlines, the ...
Inovio begins patient dosing in phase 2 segment of INNOVATE phase 2/3 trial of INO-4800 to prevent COVID-19: Plymouth Meeting, Pennsylvania Wednesday, December 9, 2020, 14:00 Hrs ...
Inovio has changed its chief commercial officer ahead of the planned launch of its first DNA medicine, putting Merck veteran Steven Egge in charge of leading the strategy and operations. The DNA ...
(Reuters) -Inovio Pharmaceuticals Inc on Tuesday expanded its partnership with Advaccine Biopharmaceuticals to conduct a late-stage trial of its COVID-19 vaccine candidate, expected to start in the ...
The biotech's lawyers have become very busy in recent months. COVID-19 caused major problems for many companies. The pandemic turned out to be a huge catalyst for Inovio, however, after the biotech ...
The stock price of Inovio Pharmaceuticals (NYSE: INO), a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, has seen a large 27% drop over the last ...
As SARS-CoV-2, the deadly coronavirus responsible for COVID-19, spread from Wuhan, China, to nearly every country around the globe, dozens of companies rushed to develop a vaccine against the novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback